Sichuan Zhishan Weixin Biotechnology
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sichuan Zhishan Weixin Biotechnology - overview
Established
2018
Location
Chengdu, Sichuan, China
Primary Industry
Biotechnology
About
Based in Chengdu, China and founded in 2018, Sichuan Zhishan Weixin Biotechnology Co. , Ltd. , trading as Sichuan Zhishan Weixin Biotechnology, is a company developing original new drugs for gene therapy, focusing on the development of original new drugs for rAAV gene therapy. The company has several patents and technologies in gene expression cassette design and vector production optimization, while the founder, Prof.
Biao Dong, has been engaged in rAAV research for years. The company's core staff has rich experience in gene therapy drug design, preclinical research, and CMC development. In December 2025, Sichuan Zhishan Weixin Biotechnology raised a series B+ funding from new investor Chengdu Science and Technology Venture Capital Group, and other investors. The company is mainly developing original new drugs for rAAV gene therapy, with a pipeline in development covering multiple clinical indications such as hematology, central nervous system, and metabolic system.
The company's first self-developed product is ZS801, an gene therapy product for hemophilia B, which has received clinical approval in August 2022. The company also has a novel pox-adenovirus rAAV production system. The company generates revenue from providing original new drugs for gene therapy.
Current Investors
Korea Investment Partners, Sichuan Venture Capital, Chengdu Tianfu International Bio-Town Investment & Development Co., Ltd.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Verticals
HealthTech, Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.